MedTrace Logo

the New Geneswell BCT in Vitro Diagnosis of Breast Cancer Prognosis

NCT04179318 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-11-27

No results posted yet for this study

Summary

Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group.

This test provides prognostic information to assess the risk of recurrence. The BCT score calculated by geneswell BCT was associated with the risk of recurrence. The higher the BCT score, the more likely it is to relapse, and vice versa.

Conditions

Interventions

DIAGNOSTIC_TEST

Geneswell BCT

Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group.

Sponsors & Collaborators

  • The Affiliated Hospital of Hangzhou Normal University

    collaborator OTHER

  • Korea University

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-10-31
Completion
2020-12-31
FDA Device
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04179318 on ClinicalTrials.gov